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ABSTRACT
With the availability of second-generation basal
insulin analogs, insulin degludec (100 and
200 units/ml [degludec]) and insulin glargine
300 units/ml (glargine U300), clinicians now
have long-acting, efficacious treatment options
with stable pharmacokinetic profiles and associated low risks of hypoglycemia that may be
desirable for many patients with type 2 diabetes. In this narrative review, we summarize
the current evidence on glycemic control in
hospitalized patients and review the pharmacokinetic properties of degludec and glargine U300
in relation to the challenges these may pose
during the hospitalization of patients with type
2 diabetes who are receiving outpatient regimens involving these newer insulins. Their
increased use in clinical practice requires that
hospital healthcare professionals (HCPs) have
appropriate protocols to transfer patients from
these second-generation insulins to formulary
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insulin on admission, and ensure the safe discharge of patients and transition back to
degludec or glargine U300. However, there is no
guidance available on this. Based on the
authors’ clinical experience, we identify key
issues to consider when arranging hospital care
of such patients. We also summarize the limited
available evidence on the potential utility of
these second-generation basal insulin analogs
in the non-critical inpatient setting and identify
avenues for future research. To address current
knowledge gaps, it is important that HCPs are
educated about the differences between standard formulary insulins and second-generation
insulins, and the importance of clear communication during patient transitions.

Keywords: Clinical
guidance;
Glycemic
control; Hospital setting; Hyperglycemia;
Hypoglycemia; Insulin degludec; Insulin
glargine U300; Transition of care
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Key Summary Points
The past decade has seen many advances
in diabetic therapies and devices
including the development and
availability of second-generation basal
insulin analogs, which have properties
that facilitate glycemic management in
the context of everyday living.
The uptake of these second-generation
basal insulin analogs in clinical practice
requires that hospital healthcare
professionals (HCPs) have appropriate
protocols to safely transfer patients from
these second-generation insulins to
formulary insulin on admission, and
ensure the safe discharge of patients and
transition back.
To address current knowledge gaps and
the limited guidance, it is important that
hospital HCPs are educated about the
differences between standard formulary
insulins and second-generation insulins,
and the importance of clear
communication during patient
transitions.

DIGITAL FEATURES
This article is published with digital features to
facilitate understanding of the article. You can
access the digital features on the articles associated Figshare page. To view digital features for
this article go to https://doi.org/10.6084/m9.
figshare.12861062.

INTRODUCTION
The past decade has seen many advances in
diabetic therapies and devices, allowing
healthcare professionals (HCPs) to better tailor
treatment strategies to patient needs [1, 2]. As
the use of these recently available therapies in
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clinical practice increases, and as the prevalence
of type 2 diabetes (T2D) continues to rise [3], it
is likely that more patients will be admitted to
the hospital on these newer therapies. At present, however, the guidance on diabetes care for
hospitalized patients does not take this into
account [4].
Among the newer treatment choices available are the second-generation basal insulin
analogs, namely insulin degludec 100 units/ml
and 200 units/ml formulations (degludec U100
and U200, respectively [bioequivalent formulations]) [5] and insulin glargine 300 units/ml
(glargine U300) [6]. These insulins have lower
variation in glucose-lowering effect (across 24 h
and from day to day) [7, 8] and a reduced risk of
hypoglycemia at a given level of HbA1c compared with previously available products [9–11].
An extended duration of action with low
peak:trough ratios at steady state also enables
some flexibility in dose timing, and these
properties all facilitate glycemic management in
the context of everyday living [12]. A few
studies investigating the use of degludec and
glargine U300 in hospitalized patients have
recently published findings, but the evidence is
limited and the nuances of insulin management
for inpatient scenarios where degludec and
glargine U300 are involved have not been fully
explored. Therefore, it is timely to take stock of
what is known about managing T2D in hospitalized patients, and it is essential to educate
HCPs about the differences between the standard formulary insulins and second-generation
insulins.
In this narrative review, we aim to summarize current evidence on glycemic control in
hospitalized patients with T2D and review the
pharmacokinetic (PK)/pharmacodynamic (PD)
properties of degludec U100 or U200 (hereafter
referred to as degludec) and glargine U300 in
relation to the challenges they may pose during
hospitalization of patients with T2D on outpatient regimens involving these insulins.

DIABETES CARE IN THE HOSPITAL
Hospitalization presents unique challenges to
glycemic control, including variation in
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nutritional status, mobility, and presence of
acute illness. A number of physiological changes (e.g., stress-induced counter-regulatory
hormone secretion) or therapeutic choices (e.g.,
glucocorticoid use) can result from acute illness
and exacerbate hyperglycemia, which, in turn,
can worsen acute illness [13]. The factors associated with hyperglycemia and hypoglycemia in
insulin-treated hospitalized patients with diabetes are summarized in Table 1; the impact of
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these must be considered when managing care.
Diabetes is rarely the primary focus of care in
hospitalized patients, and it can be difficult to
achieve glycemic control, but the increased
cost, length of stay, and adverse outcomes—
including death—that are associated with both
uncontrolled
hyperand
hypoglycemia
demonstrate how important it is [14, 15]. There
is great debate, however, on the optimal blood
glucose (BG) target for hospitalized patients.

Table 1 Factors that inﬂuence BG control in insulin-treated hospitalized patients with diabetes
Factors that increase the risk of hyperglycemia [59, 60]

Factors that increase the risk of hypoglycemia [59–62]

Patient characteristics
High insulin resistance

Advanced age

Previous poor glycemic control

Chronic kidney disease
Congestive heart failure
Duration of diabetes or insulin therapy
Food malabsorption (e.g., gastroenteritis or celiac disease)
Liver disease
Malignancies
Malnutrition
Prior episode(s) of hypoglycemia
Renal failure
Type 1 diabetes

Clinical status and therapeutic choices
Critical illness

General anesthetic or sedation

Decreased activity levels/persistent bed rest

Infection

Enteral or parenteral nutrition

New nil per os status

Increased appetite/recent end of nil per os status

Reduced or unpredictable appetite

Release of stress hormones

Renal failure

Sudden initiation, or dose increase, of concomitant corticosteroids

Sepsis
Shock
Sudden termination, or dose reduction, of corticosteroid therapy
Trauma

Diabetes management
Excessive insulin dose adjustment at admission

Failure to adjust insulin dosing with changing clinical status

Failure to adjust insulin dosing with changing clinical status

Inadequate insulin dose adjustment at admission

Inadequate or no BG monitoring

Inadequate or no BG monitoring

Insulin dispensing error

Insulin dispensing error

Interruption to BG monitoring routine (e.g., transportation off the ward)

Interruption to BG monitoring routine (e.g., transportation off the
ward)

Overfeeding/‘outside’ carbohydrate-rich food brought into hospital for the
patient

Mismatch between nutritional insulin administration and food
delivery

Factors identiﬁed from the previously published literature and the authors’ clinical experience
BG, blood glucose
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Glycemic Control in Critically Ill
Hospitalized Patients with Diabetes

perioperative period, since this is associated
with a higher incidence of hypoglycemia [14].

In 2009, the American Diabetes Association
(ADA) and the American Association of Clinical Endocrinologists issued joint guidance recommending a BG target range of 140–180 mg/
dl (7.8–10.0 mmol/l) in the majority of critically ill patients, in addition to pre-meal
(\ 140 mg/dl [7.8 mmol/l]) and spontaneous
(\ 180 mg/dl [10.0 mmol/l]) targets in most
non-critically ill patients, provided these targets can be safely achieved [15]. Evidence since
has shown that clinical outcomes may be
modified by preadmission glycemic control in
hospitalized patients [16, 17]. In one retrospective observational study, relaxed BG targets
were associated with lower mortality in critically
ill patients with poorly controlled diabetes
(HbA1c [ 7% [53 mmol/mol]), but not in patients
with well-controlled diabetes (HbA1c B 7%
[53 mmol/mol]) [16]. This led Marik and Egi to
propose differential therapeutic BG targets in
intensive care unit patients with diabetes based on
preadmission glycemic control: 140–200 mg/dl
(7.8–11.1 mmol/l) in patients with preadmission
HbA1c \ 7% (53 mmol/mol) and 160–220 mg/dl
(8.9–12.2 mmol/l) in those with preadmission
HbA1c C 7% (53 mmol/mol) [18].

Hypoglycemia in Hospitalized Patients
with Diabetes

Glycemic Control in Patients
with Diabetes Hospitalized for Surgical
Procedures
The optimal glycemic target during the perioperative period is still controversial [19]. In a
recent meta-analysis, perioperative ‘tight’
(B 150 mg/dl [8.3 mmol/l]) versus ‘liberal’
(B 220 mg/dl [12.2 mmol/l]) control was associated with reduced rates of some complications
(surgical-site infections, sepsis, atrial fibrillation, and acute kidney injury [21–43% lower]),
but there was no survival benefit, and an
increased risk of hypoglycemia (114% higher)
and severe hypoglycemia (382% higher) [19].
The 2020 ADA standards of care do not recommend glycemic targets that are any tighter than
80–180 mg/dl (4.4–10.0 mmol/l) during the

Hypoglycemia is relatively common in hospitalized patients, with prevalence ranging from 3
to 28% (depending on the definition and setting) in patients with T2D [20–22]. In hospitalized patients with diabetes, hypoglycemia is
associated with increased costs, mainly through
longer hospital stays, alongside higher rates of
morbidity and mortality [23, 24]. In critically ill
patients, hypoglycemia is independently associated with increased risk of mortality [25] and,
in non-critically ill patients (T2D: 99.4%)
admitted to hospital for infections, mortality
risk was increased by hypoglycemia (2.66 times
more likely than in patients without hypoglycemia) [26]. In combination with previous
findings [27, 28], this provides a strong evidence
base for the goal of avoiding hypoglycemia [25].
In conclusion, it appears that, while the
optimal glucose target may vary between
patients (with more research on this required),
the best outcomes are achieved when hypoglycemia is avoided and BG variability minimized. It might be appropriate (or at least
pragmatic) to relax glucose targets slightly during hospitalization, but nevertheless aim for the
best level of control that can be achieved
without incurring episodes of hypoglycemia.
Anti-Hyperglycemic Agents
in Hospitalized Patients
Insulin is the most appropriate agent for controlling glycemia in hospitalized patients
because it has no absolute contraindications, it
is the most efficacious pharmacologic agent for
lowering blood glucose, and it can be rapidly
titrated. Oral antidiabetic drugs are generally
discontinued upon admittance to hospital,
since fewer data are available on their safety in
hospitalized patients and it is not easy to adjust
their dose based on the clinical status of the
patient. In the critical care setting, continuous
intravenous insulin infusion is the preferred
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method for achieving glycemic targets, as it
allows quick correction for any sudden changes
in insulin requirements. For non-critical care,
choosing the most appropriate insulin regimen
is not as clear and the choice depends on the
individual circumstances, including whether
patients have good nutritional intake, but a
basal–bolus regimen is often the preferred regimen of choice for non-critically ill hospitalized
patients [14, 29].

degludec has been established in DEVOTE, a
dedicated cardiovascular outcomes trial [37].
Degludec is also available in an up-concentrated
formulation, insulin degludec 200 units/ml
(degludec U200), which is bioequivalent to
degludec U100 [38] and may help to address the
needs of patients with a high injection volume
burden.

SECOND-GENERATION BASAL
INSULIN ANALOGS

Glargine U300 contains the same active molecule as the first-generation basal insulin analog
glargine U100 but is an up-concentrated formulation delivering the same number of insulin units in one-third of the injection volume
[6]. After subcutaneous injection, the acidic
glargine solution is neutralized and the glargine component precipitates, forming an
amorphous depot, slowing its absorption from
subcutaneous tissue [6]. Upon redissolution,
glargine is predominantly locally converted
into a metabolite that is responsible for its
glucose-lowering effect [39]. There are differences in the PK/PD profiles between the two
glargine formulations (U100 and U300) [7],
and these are thought to result from differences in injection volume and, therefore,
depot size, leading to slower and more prolonged redissolution from a more compact
glargine U300 depot [40]. Glargine U300 has a
long duration of action (C 36 h), an elimination half-life of 18–19 h (Table 2) [6, 7], and a
more stable glucose-lowering profile than
glargine U100 [7].
In the EDITION trials program, patients with
diabetes achieved equivalent glycemic control
with glargine U300, but at a higher insulin dose
(10–18%) compared with glargine U100 [6, 9].
There were comparable or lower risks of experiencing at least one confirmed (BG B 70 mg/dl
[3.9 mmol/l]) or severe episode of hypoglycemia
at any time (24-h period) or during the night
with glargine U300 versus glargine U100 [9].
However, lower rates of hypoglycemia with
glargine U300 in the EDITION program appear
to be largely driven by data from the titration
period (week 0–week 8) and might be attributed
to differences in potency between the U100 and

This section focuses on PK/PD properties and
associated clinical outcomes of degludec and
glargine U300 in clinical practice and the
impact of their availability on insulin management of hospitalized patients with T2D.
Insulin Degludec
Degludec is a second-generation basal insulin
that forms a depot of multi-hexamer chains
after subcutaneous injection [30]. Gradual diffusion of readily absorbed degludec monomers
from this depot provides a slow delivery of
degludec into the circulation [30]. Table 2 provides an overview of its PK/PD properties.
Degludec has an ultra-long duration of action
(beyond 42 h) and an elimination half-life
of * 25 h [31]; clinicians may be concerned
that this results in an excessive accumulation of
insulin in the circulation (insulin stacking) with
once-daily dosing. However, basal insulin only
accumulates until steady state is reached, at
which time the daily injected dose is balanced
by elimination [32]. Degludec has a stable and
consistent glucose-lowering profile over the
daily dosing interval with little peak effect
[8, 31]. These properties of degludec are preserved across pediatric and elderly patients, and
those with renal or hepatic impairment [33–36].
Randomized controlled trials (RCTs) have
demonstrated comparable glycemic control and
a lower risk of hypoglycemia with degludec
compared with glargine U100 in patients with
diabetes [10, 11, 37]. The long-term safety of

Insulin Glargine U300
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Table 2 PK/PD properties and relevant practical aspects of basal insulin products
Second-generation basal insulin analogs
Degludec [5, 63]
Onset of action

1h

Time to reach
2–4 days
steady state
(OD
administration)
Elimination half- 25 h
life at steady
state

Glargine U300
[6, 64]

First-generation basal insulin analogs Intermediateacting basal
insulin
Detemir [65–68] Glargine U100
NPH insulina
[64, 65, 69]
[70–72]

B 6h

1–2 h

1–2 h

2h

B 5 daysb

2–3 doses with
BID dosing

2–4 days

3–4 dosesc

5–7 h

13–14 h

4h

\ 24 h

24 h

12 h

8–12 h

4 hd

1–3 times
daily

15–19 h

Duration of
action at steady
state

[ 42 h

Median time to
maximum
serum insulin
concentration

9h

12–16 h

6–8 h

Recommended
interval
between dose
adjustments

3–4 days

3–4 days

3 days

Recommended
timing of
injections

Any time of daye

Same time of dayf

OD dosing:
evening; BID:
once morning
and once
evening

Same time of day

Indicated in
Not been
patients
studied
6–15 years old
with type 1
diabetes; not
studied for type 2
diabetes

B 36 h

Use in special populations:
Pediatric

Indicated in
patients C 1 year
old

Indicated in
patients C 6 years
old

Indicated in
patients
2–17 years old

Elderly

Greater caution
should be
exercised

Caution should be
exercised

Greater sensitivity Caution should be
cannot be ruled
exercised
out

Not been
studied

Diabetes Ther (2020) 11:2775–2790
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Table 2 continued
Second-generation basal insulin analogs

First-generation basal insulin analogs Intermediateacting basal
insulin
Detemir [65–68] Glargine U100
NPH insulina
[64, 65, 69]
[70–72]

Degludec [5, 63]

Glargine U300
[6, 64]

Renal
impairment

No clinically
relevant PK
difference in
patients with
impairment
(versus those
without)

Not been studied

No PK difference Not been studied
in patients with
renal
impairment
(versus those
without)

Not been
studied

Hepatic
impairment

No PK difference in Not been studied
patients with
hepatic
impairment
(versus those
without)

Lower exposure in Not been studied
patients with
severe hepatic
impairment
(versus those
without)

Not been
studied

BID twice daily, detemir insulin detemir, glargine U100 insulin glargine 100 units/ml, glargine U300 insulin glargine
300 units/ml, NPH neutral protamine Hagedorn, OD once daily, PD pharmacodynamics, PK pharmacokinetic
a
If appropriately resuspended before subcutaneous injection
b
The ﬁrst dose may be insufﬁcient to cover metabolic needs in the ﬁrst 24 h of use
c
Estimated based on the theoretical number of half-lives required for trough levels to reach C 90% of the plateau
concentration
d
Mean value reported
e
With a minimum of 8 h and a maximum of 40 h between consecutive doses
f
± 3 h [47]
U300 formulations. The long-term safety of
glargine U100 has been demonstrated in the
ORIGIN cardiovascular outcomes trial [41], and
that of glargine U300 is demonstrated in the
CONCLUDE head-to-head trial [42].

Head-to-Head Studies of Degludec
and Glargine U300
Studies have compared the PK profiles of the
second-generation basal insulins and found that
degludec achieves its (more or less) peakless
profile from dose to dose more consistently
than either glargine U100 or U300 formulations
[8]. However, head-to-head trials investigating
clinical outcomes have been inconsistent in
their findings [43–45]. The latest data are from

the CONCLUDE clinical trial. This randomized,
open-label, treat-to-target trial compared the
risk of hypoglycemia with degludec U200 versus
glargine U300 over a 36-week maintenance
period (total treatment period: 88-weeks) in
1609 insulin-treated patients with T2D [42].
Although the rate of overall symptomatic
hypoglycemia (primary endpoint) was lower
with degludec U200 compared with glargine
U300 (216.8 versus 243.9 events per 100
patient-years of experience [PYE]), the difference did not reach statistical significance (RR
0.88 [0.73; 1.06]95% CI). As a result of the trial
not meeting its primary endpoint, the confirmatory testing procedure for superiority was
stopped and the prespecified confirmatory secondary hypoglycemia endpoints (nocturnal
symptomatic
hypoglycemia
and
severe
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hypoglycemia) were analyzed using prespecified
statistical models but were now considered
exploratory, since they could not be controlled
for family-wise type I error. Nevertheless, these
endpoints showed lower rates with degludec
U200 versus glargine U300 for nocturnal
symptomatic hypoglycemia (62.3 versus 93.8
events per 100 PYE, RR 0.63 [0.48; 0.84]95% CI)
and severe hypoglycemia (1.0 versus 4.9 events
per 100 PYE, RR: 0.20 [0.07; 0.57]95% CI) [42].
To summarize, it remains to be established if
one of the second-generation basal insulin
analogs currently available has an advantage
over the other for reducing risk of hypoglycemia at a given level of glycemic control
[46], but they provide a much-needed treatment
option for patients who require insulin therapy
but are fearful of, or vulnerable to,
hypoglycemia.

Diabetes Ther (2020) 11:2775–2790

nursing teams to administer insulin injections.
The steady-state profiles of degludec and glargine U300 have a markedly lower peak:trough
ratio than other insulin analogs with shorter
half-lives. Consequently, fluctuations in glucose-lowering effect are dampened and insulin
dosing errors, which are particularly prevalent
in hospitals [48], have fewer acute effects [32].
However, their long half-lives (that afford
these benefits) mean that they take longer to
achieve steady state than first-generation basal
insulins, and so titration should take place less
frequently (label recommends every 3–4 days)
than with other insulins to avoid overshooting
the BG target [5, 6]. This could make them
unsuitable for use in hospitalized patients who
may have fluctuating insulin requirements and
unstable health status.
Studies of Degludec in a Hospital Setting

Studies of Second-Generation Basal
Insulin Analogs in Hospital Settings
A lower risk of hypoglycemia and low variability in glucose-lowering effect are desirable
properties to have in an insulin used to treat
patients in the hospital setting, as well as in
clinical practice; hence, several studies are
investigating the utility of second-generation
basal insulin analogs in hospitalized patients.
The unique PK/PD profile of these newer
insulins may be of benefit in certain hospital
situations, but problematic in others. For
example, day-to-day variability in glucoselowering effect can make it challenging to dose
insulin correctly and safely, so the relatively
low day-to-day variation demonstrated by
degludec and glargine U300 may help address
this issue. In addition, these insulins are
appropriate for once-daily dosing and offer
some dosing flexibility; degludec can be injected at any time of day, and flexibly from day to
day as long as dosing is within an 8–40-h
interval following the previous dose [5]. Glargine U300 can be injected ± 3 h of the same
time each day without compromising glycemic
control [6, 47]. Such flexibility may be more
practical and safe for hospitalized patients and
those who rely on district or community

The majority of data available on degludec in
the hospital setting are from small studies, but a
large randomized trial comparing degludec with
glargine U100, as part of a basal–bolus regimen,
for the management of hospitalized and discharged patients with T2D is ongoing [49].
Findings from a small (n = 74), open-label,
randomized, controlled trial conducted in
Japanese hospitals have recently been published, albeit the patients were hospitalized for
the specific purpose of initiating insulin; hence,
the findings are not applicable to patients hospitalized as a result of acute illness/scheduled
surgery. Nevertheless, this study provides
insights into titrating degludec to target over a
short period of time [50]. In this study, patients
with
poorly
controlled
(HbA1c C 8%
[64 mmol/mol]) T2D were randomized to
receive either degludec or glargine U100 as part of
a basal–bolus regimen. Basal insulin was initiated
at 4 units before bedtime, with dose adjustment
every 2 days, and bolus insulin was started at 4
units before each meal. After 12 days, the percentage of patients achieving glycemic control
was similar between groups (* 30%), as was
the
proportion experiencing hypoglycemia
[* 41%, BG 54–70 mg/dl (3.0–3.9 mmol/l),
* 10% BG \ 54 mg/dl (3.0 mmol/l)]. The
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glycemic targets and protocol used here are
likely unsuitable for hospitalized patients, but it
is reassuring that there was no increased risk of
hypoglycemia with degludec versus glargine
U100 [50]. Furthermore, a study in 12 patients
who had a 24-h fasting period around their
scheduled colonoscopy found patients could
avoid hypoglycemia by skipping a single dose of
degludec on the morning of the procedure [51].
There are few small observational studies on
degludec use in acutely ill patients. One retrospective study assessed the impact of degludec
on 13 patients with and 13 patients without
T2D who were hospitalized and required parenteral/enteral nutrition [52]. The starting dose
of degludec was calculated according to the
carbohydrate content of the parenteral/enteral
nutrition, usually applying a 1:10 ratio of insulin units:carbohydrate (g). For patients coming
from basal–bolus insulins, the dose of shortacting insulin had to be 50% of the total daily
insulin dose at day 1, 25% at day 2, and 12.5%
at day 3, while degludec reached steady state. In
other patients, short-acting insulin was used
when BG exceeded 250 mg/dl (13.9 mmol/l). In
the T2D patients, mean glucose intake was
181 g per day, mean degludec dose was 24–26 units per day, 46.1% of patients received
short-acting insulin, and mean (SD) BG levels
improved from 210 (66.5) mg/dl [11.7 (3.7)
mmol/l to 192 (48.6) mg/dl [10.7 (2.7) mmol/l]
during the 7-day follow-up. No symptomatic or
severe hypoglycemic episodes occurred during
the hospital stay, and there was evidence of a
reduction in within-day glycemic variability (as
measured by the coefficient of variation of glycemia every 6 h) [52]. Similar results were
observed in an observational study of 52 noncritical patients with diabetes who received
degludec as part of a basal–bolus regimen while
hospitalized [53]. It is not possible to draw
conclusions on the effect and safety of degludec-based regimens in hospitalized patients
based on the current data available; it remains
to be seen whether the outcomes described in
these small observational studies will also be
observed in large, randomized trials.
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Studies of Glargine U300 in a Hospital
Setting
The largest study with published findings so far
is the glargine U300 hospital trial [54], in which
176 patients with poorly controlled T2D were
randomized to receive a basal–bolus regimen
with either glargine U300 or glargine U100 and
insulin glulisine before meals after admission to
hospital. Insulin-experienced patients received
80% of their total daily outpatient insulin dose,
and starting dose for insulin-naı̈ve patients was
determined according to weight and glycemic
control: 0.4 and 0.5 units/kg/day for patients
with BG levels of 140–200 and 201–400 mg/dl
[7.8–11.1 and 11.2–22.2 mmol/l], respectively.
The total daily dose was split evenly between
basal and prandial insulin, the latter divided in
three equal doses before meals. The final titration protocol was to adjust basal and rapid-acting doses on a daily basis with increases of 10%
[BG 140–180 mg/dl (7.8–10.0 mmol/l), 20% (BG
180–240 mg/dl (10.0–13.3 mmol/l)], and 30%
[BG [ 240 mg/dl (13.3 mmol/l)] if patients were
in poor glycemic control, but, during the first
6 months of study (before the first prespecified
interim analysis), adjustments were only made
if BG was [ 180 mg/dl (10.0 mmol/l). Mean
(SD) BG at admission was 228 (82) mg/dl [12.7
(4.6) mmol/l], and this improved in both treatment arms, with mean daily BG levels of 186
(40) mg/dl [10.3 (2.2) mmol/l] for the glargine
U100 group and 184 (46) mg/dl [10.2 (2.6)
mmol/l] with glargine U300. The median (interquartile range [IQR]) inpatient stay was 6 (4;
8) days with glargine U300 and 4 (3; 7) days
with glargine U100, and, overall, the level of
glycemic control achieved was not impacted by
duration of hospital stay. Capillary point-ofcare testing before meals and bedtimes revealed
that the percentages of patients with
BG \ 70 mg/dl (3.9 mmol/l) were similar
between the glargine U100 group (8.7%) and
the glargine U300 group (9.5%), but clinically
significant
hypoglycemia
(BG \ 54 mg/dl
[3.0 mmol/l]) occurred in 6% of glargine U100treated patients versus 0% of glargine U300treated patients (p = 0.02), and a single episode
of
severe
hypoglycemia
(BG \ 40 mg/dl
[2.2 mmol/l]) occurred with glargine U100.
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There were no significant differences in glycemic control in a subset of 82 patients using
continuous glucose monitoring during their
stay.

Challenges of Interrupting Treatment
with Second-generation Basal Insulin
Analogs during Hospitalization
Not all hospital formularies include secondgeneration basal insulins, so patients may need
to be transferred to the available formulary
basal insulin, and, in some cases, it might be
more practical or desirable to transfer patients
temporarily to continuous intravenous (IV)
insulin infusion. The current lack of data and
restricted formularies will mean that the vast
majority of patients being treated with degludec
or glargine U300 are likely to be switched to an
insulin with a shorter half-life. Despite this,
there are no guidelines on safely switching
between second- and first-generation basal
insulin analogs upon admittance and discharge
from hospital [4]. While the prescribing information gives recommendations on how to
switch to these newer insulins (unit-for-unit
conversions except when switching from twicedaily basal insulin to glargine U300, where a
20% dose reduction is recommended) [5, 6], it is
unknown whether these are suitable for
patients who may have just undergone major
changes in glucose handling before being discharged from hospital, and there is even less
information on switching from these insulins.
Table 3 presents a comparison of guidance
(drawn from the authors’ clinical experience)
on the hospital care of patients with T2D
receiving outpatient basal insulin regimens
involving a first- or second-generation basal
insulin analog.
In a recent paper, Hirsch and Draznin
explored several clinical scenarios in which
challenges may arise when switching from
degludec to a basal insulin with a shorter halflife [4]. The authors surveyed 30 other HCPs on
what they would do in each situation, and also
offered their own recommendation, based on
the PK/PD profile of the insulins involved. The
most popular answer selected by HCPs often
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involved making unit-to-unit conversions
between degludec and formulary insulins, but
this may not be appropriate, especially in hospitalized patients who are vulnerable to hypoglycemia, because of the carry-over effect of
previously injected degludec. For patients
admitted to the hospital on degludec, the
authors recommended halving their basal
insulin dose on the first day they are switched
to a first-generation formulary basal insulin and
then upping the dose to 75–100% of the preadmittance insulin dose the next day (depending on BG levels) [4]. This is based on the
knowledge that 50% of the last degludec dose is
still contributing to the serum insulin levels
25 h post-injection, as indicated by the terminal
half-life. This is a conservative approach to
avoid hypoglycemia when switching from a
second- to first-generation basal insulin in hospitalized patients. It is important to consider
when exactly the patient’s last dose was given,
especially given the flexibility in degludec dosing. For example, if the last dose of insulin
(degludec) was [ 30 h ago, halving the next
dose of insulin (e.g., glargine U100, onset of
action B 6 h) may result in a temporary rise in
glycemia. It is impossible to provide a precise
and universal calculation for conversion, as
every situation is different, and the factors listed
in Table 1 will also determine patients’ insulin
requirements. Nevertheless, we would recommend considering a reduction in total daily
insulin dose of between 20 and 50% when
switching non-critical patients from degludec to
a first-generation basal insulin upon admittance
to hospital and a similar magnitude in dose
reduction when switching back to degludec
upon discharge to reduce the risk of
hypoglycemia.
While Hirsch and Draznin discussed the
challenges pertaining to degludec, to the best of
our knowledge, these same challenges have not
been explored with explicit reference to glargine U300. For the most part, the same principles will apply; indeed, the glargine U300
hospital trial reduced insulin dose by 20% when
switching from U100 to U300 formulations.
However, given the relatively shorter half-life
and lower unit dose potency of glargine U300
compared with degludec, somewhat smaller
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Table 3 Comparison of guidance (drawn from the authors’ clinical experience) for the hospital care of patients with type 2
diabetes receiving outpatient basal insulin regimens
Guidance for outpatient regimens involving a second-generation basal insulin analog (degludec or glargine U300)
Similarities to guidance for other outpatient basal insulin analogsa

Differences from clinical guidance for other outpatient basal insulin
analogsa

Hospital admission
Assessment of outpatient glycemic control and review of hyper- and
hypoglycemia
Setting inpatient glycemic goals
Hospitalization
Choice of therapeutic regimen and the factors that inﬂuence this choice
Use of formulary insulin products, as required
Decision to discontinue other non-insulin glucose-lowering agents
Adjustment of insulin dose according to clinical status and to
accommodate for changes in meals and activity levels, the effects of illness,
and other medications (for degludec only)
Targeting a BG range
Scheduled POC BG testing (after 48 h)

At least a 20% reduction in total daily insulin dose when transferring a
patient from second-generation basal insulin analogs to formulary insulin
productsa to reduce the hypoglycemia risk
Extra scheduled POC BG tests at 00:00 and 03:00 for the ﬁrst 48 h
If the patient remains on the second-generation basal insulin analog in
hospital, the basal insulin dose should be titrated no more frequently than
every 3–4 days, with adjustments made to nutritional and/or
supplemental insulin dosing as required and the patient should be closely
followed up

Use of protocols to avoid and manage hypoglycemia
Evaluation of BG records (POC and laboratory test results) and
adjustment of nutritional and/or correctional insulin dose
Discharge from hospital
Written and verbal instructions on self-monitoring of BG, an explanation
of home BG goals, and the importance of consistent nutritional habits
Caution that BG levels may be higher than normal for a few days after
discharge
Transfer from formulary insulin productsa to the previous basal insulin
analog: convert the basal insulin dose on a unit-per-unit basis with
glargine U300
Reintroduction and dosing of any non-insulin glucose lowering agents (if
discontinued during hospitalization)

Emphasis that BG levels may be higher than normal for a few days after
discharge, with verbal and written instructions advising that the basal
insulin dose should be titrated no more frequently than every 3–4 days to
avoid overshooting the BG target, putting the patient at risk of
hypoglycemia
Consider at least a 20% dose reduction in the hospital formulary basal
insulina dose to the degludec dose to be conservative
Provide verbal and written instructions to the patient that it may take up to
4 days to see the full effect of degludec or up to 5 days to see the full effect
of glargine U300

Therapeutic intensiﬁcation or adjustment, if required
Scheduling of follow-up visits
BG blood glucose, glargine U300 insulin glargine 300 units/ml, POC point of care
a
First-generation basal insulin analogs (e.g., insulin glargine 100 units/ml or insulin detemir)

dose reductions may be appropriate when
switching between glargine U300 and formulary
insulin.
Another important point to consider when
adjusting insulin during hospitalization is
whether the patient’s pre-admission insulin
dose was appropriate. In cases where patient
adherence is poor, the insulin dose can sometimes be inappropriately increased. Therefore, it
may be best to also consider the insulin dose
expected based on the patient’s body weight
and nutritional needs. This scenario is possibly
less likely, however, in patients on degludec/
glargine U300 regimens, as the impact of

missing a basal insulin dose becomes smaller as
the half-life increases.
Admitting a Patient on Newer Therapies
to Hospital
While there may not be enough evidence to
draw conclusions on the utility of starting second-generation basal insulin analogs in hospitalized patients, the findings so far may help
HCPs decide whether patients who are already
being treated with a newer basal insulin should
remain on that insulin during their hospital
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stay or be switched to an insulin with a shorter
half-life. For example, the findings from the
glargine U300 hospital trial do not indicate that
a patient with T2D poorly controlled with
glargine U300 would have better outcomes by
being switched to glargine U100 upon admittance. This may mean that HCPs take the decision to keep patients on glargine U300
throughout, thereby avoiding the challenges
and potential risks associated with switching
between a first- and second-generation basal
insulin. However, further study is required to
support hospital HCPs in this decision and to
ensure that future guidelines contain sufficient
information on the challenges these new therapies pose to insulin management in an inpatient setting.
Discharging a Patient from Hospital
Formulary Insulin Back to Their PreAdmission Regimen
Irrespective of the inpatient diabetes treatment
regimen, the transition of care from the inpatient to the outpatient setting represents a
clinical challenge [55]. Discharge planning
should commence at hospital admission and
include steps to ensure appropriate communication across caregivers, reconciling medication across the continuum of care, arranging
for timely follow-up, and encouraging active
involvement from patients in their diabetes
care [55]. Additional steps are advisable for
patients switching back from the hospital formulary insulin to their pre-admission regimen
involving a second-generation basal insulin
analog (Table 3). For instance, patients should
receive verbal and written instructions advising
that the second-generation basal insulin dose
should be titrated no more frequently than
every 3–4 days to avoid overshooting the BG
target, putting the patient at risk of hypoglycemia. A dose reduction should be considered in patients switching back to their home
regimen involving degludec, while patients
should be advised that it may take up to 4 days
to see the full effect of degludec or up to 5 days
to see the full effect of glargine U300 following
discharge (Table 3).
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COVID-19 Infection in Patients with T2D
Due to the recent emergence of COVID-19,
there has not been an opportunity to study the
relationship between T2D and susceptibility to
COVID-19 infection in large cohorts; thus, a
conclusive relationship is yet to be determined.
However, retrospective studies of hospitalized
patients with COVID-19 have demonstrated
that, compared with non-diabetic patients,
patients with T2D require more intensive
treatments in the management of COVID-19
symptoms, and have a significantly higher inhospital death rate [56]. Furthermore, wellcontrolled BG levels during COVID-19 infection
are associated with better survival [56]. One
retrospective study, although limited by patient
numbers, indicated that patients with T2D who
are critically ill with COVID-19 seem have a
greater need for insulin at the peak of their
COVID-19 infection [57]. The management of
diabetes in patients with COVID-19 poses a
clinical challenge that requires a balance
between glucose-lowering treatments and
treatments to manage the viral infection, in
addition to careful consideration regarding the
multiple factors that contribute to poor prognosis in patients with both COVID-19 and T2D
[58]. The authors feel that it is too early to discuss the use of second-generation basal insulin
analogs in COVID-19 patients.
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CONCLUSIONS
Optimal use of insulin in hospitalized patients
with diabetes remains to be fully elucidated and
continues to be a subject of ongoing study. The
increased use of second-generation basal insulin
analogs in clinical practice presents hospital
HCPs with a challenge, since there is no guidance available on how to safely switch
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hospitalized patients from second- to first-generation basal insulin analogs. As more data
become available on the possible utility of these
newer insulins as part of a basal–bolus regimen
in the hospital setting, hospital HCPs will be
better able to decide whether non-critically ill
patients can remain on their ultra-long-acting
basal insulin. In any case, a carefully considered
treatment plan for each individual patient is
required, and this may require thought to be
given to the initiation, continuation, adjustment, discontinuation, and recommencement
of these insulins.
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